Evidence map›Paper›PMID 32918498›Full record

ArticleJournal of clinical laboratory analysis2021

Diagnostic value of macrophage inhibitory cytokine 1 as a novel prognostic biomarkers for early gastric cancer screening.

Xin Ge, Xiaolei Zhang, Yanling Ma, Shaohua Chen, Zhaowu Chen, Ming Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical laboratory analysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Xin GeDepartment of Laboratory Diagnostics, The First Affiliated Hospital of University of Science and Technology of China, Hefei, P.R. China.
Xiaolei ZhangDepartment of Laboratory Diagnostics, The First Affiliated Hospital of University of Science and Technology of China, Hefei, P.R. China.
Yanling MaAnhui Office for Cancer Control and Research, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, P.R. China.
Shaohua ChenDepartment of Laboratory Diagnostics, The First Affiliated Hospital of University of Science and Technology of China, Hefei, P.R. China.
Zhaowu ChenDepartment of Laboratory Diagnostics, The First Affiliated Hospital of University of Science and Technology of China, Hefei, P.R. China.
Ming LiDepartment of Laboratory Diagnostics, The First Affiliated Hospital of University of Science and Technology of China, Hefei, P.R. China.ORCID https://orcid.org/0000-0002-2106-034X
University of Science and Technology of China · CN

Funding

The Fundamental Research Funds for the Central University WK9110000025The National Cancer Center Climbing Funds NCC201812B036The Natural Science Foundation of Anhui Province 2008085MH288
6 · The paper itself

Abstract

backgroundEarly diagnosis is very important to improve the survival rate of patients with gastric cancer (GC), especially in asymptomatic participants. However, low sensitivity of common biomarkers has caused difficulties in early screening of GC. In this study, we explored whether MIC-1 can improve the detection rate of early GC.

methodsWe screened 8257 participants based on risk factors such as age, gender, and family history for physical examination including gastroscopy. Participant blood samples were taken for measure MIC-1, CA-199, CA72-4, and PG1/PG2 levels. The diagnostic performance of MIC-1 was assessed and compared with CA-199, CA72-4, and PG1/PG2, and its role in early GC diagnosis and the assessment of the risk of precancerous lesions have also been studied.

resultsBased on endoscopic and histopathological findings, 55 participants had GC, 566 participants had low-grade neoplasia, and 2605 participants had chronic gastritis. MIC-1 levels were significantly elevated in GC serum samples as compared to controls (P < .001). The sensitivity of serum MIC-1 for GC diagnosis was much higher than that of CA-199 (49.1% vs 20.0%) with similar specificities. Moreover, receiver operating characteristic (ROC) curve analysis also showed that serum MIC-1 had a better performance compared with CA-199, CA72-4, and PG1/PG2 in distinguishing early-stage GC (AUC: 72.9% vs 69.5%, 67.5%, 44.0%, respectively).

conclusionsSerum MIC-1 is significantly elevated in most patients with early GC. MIC-1 can serve as a novel diagnostic marker of early GC and value the risk of GC.

Indexed as

AdultBiomarkers, TumorEarly Detection of CancerFemaleGrowth Differentiation Factor 15HumansMalePrognosisSensitivity and SpecificityStomach NeoplasmsBiomarkers, TumorGDF15 protein, humanGrowth Differentiation Factor 15biomarkersgastric cancerMIC-1

Identifiers

PMID32918498
PMCPMC7843257
OpenAlexW3086449959

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.